Corteva (NYSE:CTVA – Get Free Report) had its price target increased by investment analysts at CICC Research from $80.00 to $93.00 in a report released on Wednesday,MarketScreener reports. The firm currently has an “outperform” rating on the stock. CICC Research’s price objective would suggest a potential upside of 12.45% from the stock’s previous close.
CTVA has been the topic of several other reports. JPMorgan Chase & Co. lowered shares of Corteva from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $75.00 to $77.00 in a research report on Thursday, February 5th. Jefferies Financial Group raised their price target on Corteva from $95.00 to $97.00 in a research report on Thursday, May 7th. Royal Bank Of Canada lifted their price target on Corteva from $95.00 to $97.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. The Goldman Sachs Group boosted their price objective on shares of Corteva from $88.00 to $96.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. Finally, BNP Paribas Exane increased their price objective on shares of Corteva from $74.00 to $77.00 in a research note on Wednesday, May 6th. Thirteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Corteva presently has a consensus rating of “Moderate Buy” and an average price target of $88.14.
View Our Latest Analysis on Corteva
Corteva Stock Up 0.1%
Corteva (NYSE:CTVA – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.18 by $0.32. The business had revenue of $4.91 billion for the quarter, compared to analyst estimates of $4.64 billion. Corteva had a net margin of 6.50% and a return on equity of 9.95%. The business’s revenue was up 11.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.13 earnings per share. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, analysts forecast that Corteva will post 3.7 earnings per share for the current year.
Insider Activity at Corteva
In other news, insider Brian Titus sold 8,311 shares of Corteva stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $76.55, for a total transaction of $636,207.05. Following the completion of the sale, the insider directly owned 8,090 shares in the company, valued at $619,289.50. The trade was a 50.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.15% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Corteva
Hedge funds have recently modified their holdings of the stock. Activest Wealth Management grew its stake in shares of Corteva by 118.3% during the 3rd quarter. Activest Wealth Management now owns 369 shares of the company’s stock valued at $25,000 after buying an additional 200 shares during the period. JPL Wealth Management LLC purchased a new position in shares of Corteva in the 3rd quarter worth $25,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Corteva in the 4th quarter worth $27,000. Bank of Jackson Hole Trust acquired a new position in Corteva in the fourth quarter valued at $28,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in Corteva during the third quarter valued at about $29,000. 81.54% of the stock is owned by institutional investors and hedge funds.
About Corteva
Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.
Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.
Featured Stories
- Five stocks we like better than Corteva
- Dream Finders Homes’ Hostile Bid Creates a Dual Squeeze Play
- Why OpenAI’s IPO Plans Could Be a Massive Win for Microsoft
- A Real Biggie Deal: Wendy’s Serves Up a Juicy Buyout Arbitrage
- Ally Financial Is Back to Basics—And Investors Are Watching
Receive News & Ratings for Corteva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corteva and related companies with MarketBeat.com's FREE daily email newsletter.
